BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro Biopharma Eli Lilly and Co. AbCellera Biologics Inc. Cedars-Sinai Medical Center UnitedHealth...
BioCentury | May 26, 2020
Distillery Therapeutics

Disrupting mitochondrial DNA-mediated paracrine signaling for prostate cancer

...online April 1, 2020 doi:10.1073/pnas.1910952117 CONTACT: Neil A. Bhowmick, Cedars-Sinai Medical Center, Los Angeles, Calif. email: bhowmickn@cshs.org Claire Quang Cedars-Sinai Medical Center Complement...
BioCentury | Jun 19, 2019
Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

...published online Jun. 12, 2019 doi:10.1126/scitranslmed.aat9284 CONTACT: Ekihiro Seki, Cedars-Sinai Medical Center, Los Angeles, Calif. email: ekihiro.seki@cshs.org Claire Quang Cedars-Sinai Medical Center Hyaluronan...
BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting CARD9 for colitis and Crohn's disease

...online March 5, 2019 doi:10.1016/j.chom.2019.01.007 CONTACT: David M. Underhill, Cedars-Sinai Medical Center, Los Angeles, Calif. email: david.underhill@csmc.edu Claire Quang Cedars-Sinai Medical Center Caspase...
BioCentury | Feb 26, 2019
Distillery Therapeutics

Cancer

...Feb. 22, 2019 doi:10.1126/sciadv.eaav2437 CONTACT: Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, Calif. email: dan.theodorescu@cshs.org Claire Quang Sprycel, dasatinib (BMS-354825) Cedars-Sinai Medical Center Discoidin...
BioCentury | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

...SCC) of the cervix, esophagus, head and neck, and lung National University of Singapore ; Cedars-Sinai Medical Center...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...2018 doi:10.1172/JCI99397 CONTACT: Neil A. Bhowmick, Cedars-Sinai Medical Center, Los Angeles, Calif. email: bhowmickn@cshs.org Mark Zipkin Xtandi, enzalutamide (mdv3100, p-INN) Cedars-Sinai Medical Center Androgen...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...University of Singapore, Singapore email: jyy.36000@gmail.com CONTACT: De-Chen Lin, Cedars-Sinai Medical Center, Los Angeles, Calif. email: dchlin11@gmail.com Claire Quang Cedars-Sinai Medical Center National...
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

...I or Phase II study data,” said Heather McArthur, medical director of breast oncology at Cedars-Sinai Medical Center...
...Va. Armo BioSciences Inc. (NASDAQ:ARMO), Redwood City, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cedars-Sinai Medical Center...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...the focus of only about one-fifth. According to an abstract presented by a collaboration between Cedars-Sinai Medical Center...
...Santiago, Chile AstraZeneca plc (NYSE:AZN; LSE:AZN), London, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cedars-Sinai Medical Center...
Items per page:
1 - 10 of 116
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro Biopharma Eli Lilly and Co. AbCellera Biologics Inc. Cedars-Sinai Medical Center UnitedHealth...
BioCentury | May 26, 2020
Distillery Therapeutics

Disrupting mitochondrial DNA-mediated paracrine signaling for prostate cancer

...online April 1, 2020 doi:10.1073/pnas.1910952117 CONTACT: Neil A. Bhowmick, Cedars-Sinai Medical Center, Los Angeles, Calif. email: bhowmickn@cshs.org Claire Quang Cedars-Sinai Medical Center Complement...
BioCentury | Jun 19, 2019
Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

...published online Jun. 12, 2019 doi:10.1126/scitranslmed.aat9284 CONTACT: Ekihiro Seki, Cedars-Sinai Medical Center, Los Angeles, Calif. email: ekihiro.seki@cshs.org Claire Quang Cedars-Sinai Medical Center Hyaluronan...
BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting CARD9 for colitis and Crohn's disease

...online March 5, 2019 doi:10.1016/j.chom.2019.01.007 CONTACT: David M. Underhill, Cedars-Sinai Medical Center, Los Angeles, Calif. email: david.underhill@csmc.edu Claire Quang Cedars-Sinai Medical Center Caspase...
BioCentury | Feb 26, 2019
Distillery Therapeutics

Cancer

...Feb. 22, 2019 doi:10.1126/sciadv.eaav2437 CONTACT: Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, Calif. email: dan.theodorescu@cshs.org Claire Quang Sprycel, dasatinib (BMS-354825) Cedars-Sinai Medical Center Discoidin...
BioCentury | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

...SCC) of the cervix, esophagus, head and neck, and lung National University of Singapore ; Cedars-Sinai Medical Center...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...2018 doi:10.1172/JCI99397 CONTACT: Neil A. Bhowmick, Cedars-Sinai Medical Center, Los Angeles, Calif. email: bhowmickn@cshs.org Mark Zipkin Xtandi, enzalutamide (mdv3100, p-INN) Cedars-Sinai Medical Center Androgen...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...University of Singapore, Singapore email: jyy.36000@gmail.com CONTACT: De-Chen Lin, Cedars-Sinai Medical Center, Los Angeles, Calif. email: dchlin11@gmail.com Claire Quang Cedars-Sinai Medical Center National...
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

...I or Phase II study data,” said Heather McArthur, medical director of breast oncology at Cedars-Sinai Medical Center...
...Va. Armo BioSciences Inc. (NASDAQ:ARMO), Redwood City, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cedars-Sinai Medical Center...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...the focus of only about one-fifth. According to an abstract presented by a collaboration between Cedars-Sinai Medical Center...
...Santiago, Chile AstraZeneca plc (NYSE:AZN; LSE:AZN), London, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cedars-Sinai Medical Center...
Items per page:
1 - 10 of 116